Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 1 2

Status

Terminated 1Recruiting 1Completed 1

Sponsor Class

OTHER 1NETWORK 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 2Sarcoma 1Gastrointestinal 1

Conditions

Sarcoma, Ewing 1Rhabdomyosarcoma 1Osteosarcoma 1Neuroblastoma 1Microphthalmia, Isolated, with Coloboma 5 1Medulloblastoma 1Liposarcoma 1Cholangiocarcinoma 1Biliary Tract Neoplasms 1Bile Duct Neoplasms 1

Interventions

pembrolizumab 410Cyclophosphamide 394Carboplatin 306Gemcitabine 286Nivolumab 276Paclitaxel 274Cisplatin 252Radiotherapy 225Dexamethasone 210Bevacizumab 209fludarabine 192Docetaxel 187Rituximab 183Capecitabine 171Oxaliplatin 158Lenalidomide 157Fluorouracil 152Temozolomide 138Cytarabine 135Etoposide 128Irinotecan 124Cetuximab 123fludarabine phosphate 120Injections 118venetoclax 116Ipilimumab 115Doxorubicin 114Azacitidine 108130-nm albumin-bound paclitaxel 108Pemetrexed 107

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × silmitasertib × Clear all
NCT06541262 2026-04-09

Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors

Milton S. Hershey Medical Center

Phase 1/2 Recruiting
104 enrolled
CNSSarcoma

Liposarcoma, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma

NCT03904862 2025-10-30

Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery

Pediatric Brain Tumor Consortium

Phase 1/2 Terminated
21 enrolled
CNS

Microphthalmia, Isolated, with Coloboma 5, Medulloblastoma

NCT02128282 2021-10-22

Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma

Senhwa Biosciences, Inc.

Phase 1/2 Completed
127 enrolled
Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡